May 2024 SOCRA Source Journal - Journal - Page 53
References (continued
Lehmann, B. D. and Pietenpol, J. A. (2015) ‘Clinical implications of molecular heterogeneity in triple negative
breast cancer’, The Breast, 24, S36-S40.
Liedtke, C. and Rody, A. (2015) ‘New treatment strategies for patients with triple-negative breast cancer’,
Current Opinion in Obstetrics and Gynecology, 27(1), 77-84.
Luo, X., Shi, Y., Li, Z. and Jiang, W. (2010) ‘Expression and clinical signi昀椀cance of androgen receptor in triple
negative breast cancer’, Chin J Cancer, 29(6), 585-590.
Manavi, M., Hudelist, G., Fink-Retter, A., Gschwandtler-Kaulich, D., Pischinger, K. and Czerwenka, K. (2007)
‘Gene pro昀椀ling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma’,
Gynecologic Oncology, 105(2), 418-426.
Montagna, E., Maisonneuve, P., Rotmensz, N., Cancello, G., Ior昀椀da, M., Balduzzi, A., Galimberti, V., Veronesi, P.,
Luini, A. and Pruneri, G. (2013) ‘Heterogeneity of triple-negative breast cancer: histologic subtyping to inform
the outcome’, Clinical Breast Cancer, 13(1), 31-39.
Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M. and Bhargava, R. (2010) ‘Androgen receptor in
breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with
apocrine differentiation’, Modern Pathology, 23(2), 205-212.
O’Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M. and
Bradley, C. (2011) ‘Iniparib plus chemotherapy in metastatic triple-negative breast cancer’, New England
Journal of Medicine, 364(3), 205-214.
Onitilo, A. A., Engel, J. M., Greenlee, R. T. and Mukesh, B. N. (2009) ‘Breast cancer subtypes based on ER/PR
and Her2 expression: comparison of clinicopathologic features and survival’, Clinical Medicine & Research,
7(1-2), 4-13.
Oualla, K., El-Zawahry, H. M., Arun, B., Reuben, J. M., Woodward, W. A., Gamal El-Din, H., Lim, B., Mellas, N.,
Ueno, N. T. and Fouad, T. M. (2017) ‘Novel therapeutic strategies in the treatment of triple-negative breast
cancer’, Therapeutic Advances in Medical Oncology, 1758834017711380.
Pareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B. and Reis-Filho, J. S. (2016) ‘Triple-negative
breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants’,
NPJ Breast Cancer, 2, 16036.
Perou, C. M., Jeffrey, S. S., Van De Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams,
C. F., Zhu, S. X. and Lee, J. C. (1999) ‘Distinctive gene expression patterns in human mammary epithelial cells
and breast cancers’, Proceedings of the National Academy of Sciences, 96(16), 9212-9217.
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T.,
Johnsen, H. and Akslen, L. A. (2000) ‘Molecular portraits of human breast tumours’, Nature, 406(6797),
747-752.
Persson, I. (2000) ‘Estrogens in the causation of breast, endometrial and ovarian cancers—evidence and
hypotheses from epidemiological 昀椀ndings’, The Journal of Steroid Biochemistry and Molecular Biology, 74(5),
357-364.
Ribnikar, D., Volovat, S. R. and Cardoso, F. (2019) ‘Targeting CDK4/6 pathways and beyond in breast cancer’,
The Breast, 43, 8-17.
SOCRA SOURCE © May 2024
53